SCHEMBL14924014

SCHEMBL14924014

O=C(Cl)/C=C/c1cccc(CO)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
PKM P14618 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
HDAC4 P56524 3/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
MEF2D Q14814 2/20 0.44
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
HPGD P15428 1/20 0.43
MMP1 P03956 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL853485 0.86 NPSR1 (0.61) TRPV1ALDH1A1KDM4EPKMCYP2C9
SCHEMBL853486 0.86 NPSR1 (0.61) TRPV1ALDH1A1KDM4EPKMCYP2C9
SCHEMBL10981903 0.83 CYP1A2 (0.57) ALDH1A1CYP1A2CYP2C9NPSR1HDAC4
SCHEMBL7927174 0.83 CYP1A2 (0.57) ALDH1A1CYP1A2CYP2C9NPSR1HDAC4
SCHEMBL15026335 0.83 NPSR1 (0.49) TRPV1ALDH1A1KDM4EPKMCYP1A2
SCHEMBL3295979 0.79 TTR (0.54) TRPV1ALDH1A1KDM4EPKMHDAC4
SCHEMBL28068831 0.79 MAOB (0.64) ALDH1A1PKMHDAC4HDAC3HDAC1
SCHEMBL28068830 0.79 MAOB (0.64) ALDH1A1PKMHDAC4HDAC3HDAC1
SCHEMBL14769851 0.79 TRPV1 (0.44) TRPV1ALDH1A1KDM4EPKMCYP1A2
SCHEMBL3295973 0.79 TTR (0.54) TRPV1ALDH1A1KDM4EPKMHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604931-B2 Nuclear receptor binding agents GTX, INC. (US) 2017-03-28 US disclosed
US-20170014401-A1 NUCLEAR RECEPTOR BINDING AGENTS GTX, INC. 2017-01-19 US disclosed
US-20130150403-A1 NUCLEAR RECEPTOR BINDING AGENTS VA Long Beach Healthcare System (US) 2013-06-13 US disclosed
US-20130116277-A1 ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS DALTON JAMES T (US) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170014401-A1 NUCLEAR RECEPTOR BINDING AGENTS ESRRB, ESRRG, ESRRA TRPV1 1837/4885ALDH1A1 1489/4885KDM4E 1789/4885
US-20130150403-A1 NUCLEAR RECEPTOR BINDING AGENTS FABP3, NCOR1, NR3C2 TRPV1 2040/4885ALDH1A1 1844/4885KDM4E 3187/4885
US-20130116277-A1 ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS AKR1C3, AKR1C1, AKR1C2 TRPV1 3440/4885ALDH1A1 250/4885KDM4E 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.